Who might be predisposed to the development of serious side effects when treated with TNF-alpha antagonist?
Kotyla
P J
PJ
Kucharz
E J
EJ
D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D000075202:Contraindications; D005260:Female; D006333:Heart Failure / Q000209:etiology* / Q000503:physiopathology; D006801:Humans; D000069285:Infliximab; D012307:Risk Factors; D017180:Tachycardia, Ventricular / Q000209:etiology* / Q000503:physiopathology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D018487:Ventricular Dysfunction, Left / Q000209:etiology / Q000503:physiopathology
D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab